Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.92
RDY's Cash to Debt is ranked lower than
63% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. RDY: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
RDY' s 10-Year Cash to Debt Range
Min: 0.12  Med: 0.69 Max: 33.44
Current: 0.92
0.12
33.44
Equity to Asset 0.57
RDY's Equity to Asset is ranked lower than
58% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. RDY: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
RDY' s 10-Year Equity to Asset Range
Min: 0.32  Med: 0.53 Max: 0.82
Current: 0.57
0.32
0.82
Interest Coverage 24.07
RDY's Interest Coverage is ranked lower than
71% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. RDY: 24.07 )
Ranked among companies with meaningful Interest Coverage only.
RDY' s 10-Year Interest Coverage Range
Min: 2.17  Med: 20.43 Max: 1038.42
Current: 24.07
2.17
1038.42
F-Score: 5
Z-Score: 6.98
M-Score: -2.40
WACC vs ROIC
2.97%
18.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 17.74
RDY's Operating margin (%) is ranked higher than
79% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. RDY: 17.74 )
Ranked among companies with meaningful Operating margin (%) only.
RDY' s 10-Year Operating margin (%) Range
Min: -4.08  Med: 16.91 Max: 30.47
Current: 17.74
-4.08
30.47
Net-margin (%) 14.97
RDY's Net-margin (%) is ranked higher than
79% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. RDY: 14.97 )
Ranked among companies with meaningful Net-margin (%) only.
RDY' s 10-Year Net-margin (%) Range
Min: -7.44  Med: 14.33 Max: 29.6
Current: 14.97
-7.44
29.6
ROE (%) 22.05
RDY's ROE (%) is ranked higher than
84% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. RDY: 22.05 )
Ranked among companies with meaningful ROE (%) only.
RDY' s 10-Year ROE (%) Range
Min: -11.56  Med: 21.27 Max: 47.58
Current: 22.05
-11.56
47.58
ROA (%) 12.33
RDY's ROA (%) is ranked higher than
82% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. RDY: 12.33 )
Ranked among companies with meaningful ROA (%) only.
RDY' s 10-Year ROA (%) Range
Min: -6.1  Med: 12.11 Max: 31.93
Current: 12.33
-6.1
31.93
ROC (Joel Greenblatt) (%) 32.32
RDY's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. RDY: 32.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RDY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7.46  Med: 31.82 Max: 122.55
Current: 32.32
-7.46
122.55
Revenue Growth (3Y)(%) 15.10
RDY's Revenue Growth (3Y)(%) is ranked higher than
70% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. RDY: 15.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RDY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.4  Med: 15.05 Max: 46.1
Current: 15.1
0.4
46.1
EBITDA Growth (3Y)(%) 14.50
RDY's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. RDY: 14.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RDY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -37  Med: 20.80 Max: 154.4
Current: 14.5
-37
154.4
EPS Growth (3Y)(%) 15.70
RDY's EPS Growth (3Y)(%) is ranked higher than
65% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. RDY: 15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RDY' s 10-Year EPS Growth (3Y)(%) Range
Min: -65  Med: 32.55 Max: 154.7
Current: 15.7
-65
154.7
» RDY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

RDY Guru Trades in Q3 2014

Ken Fisher 3,994,868 sh (+5.88%)
Jeremy Grantham Sold Out
Sarah Ketterer 167,800 sh (-13.86%)
» More
Q4 2014

RDY Guru Trades in Q4 2014

Sarah Ketterer 603,012 sh (+259.36%)
Ken Fisher 4,153,572 sh (+3.97%)
» More
Q1 2015

RDY Guru Trades in Q1 2015

Jim Simons 4,000 sh (New)
Ken Fisher 5,216,225 sh (+25.58%)
Sarah Ketterer 535,100 sh (-11.26%)
» More
Q2 2015

RDY Guru Trades in Q2 2015

Ken Fisher 5,198,254 sh (-0.34%)
» More
» Details

Insider Trades

Latest Guru Trades with RDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.12
RDY's P/E(ttm) is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. RDY: 31.12 )
Ranked among companies with meaningful P/E(ttm) only.
RDY' s 10-Year P/E(ttm) Range
Min: 10.6  Med: 24.15 Max: 430.4
Current: 31.12
10.6
430.4
Forward P/E 27.10
RDY's Forward P/E is ranked lower than
53% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. RDY: 27.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.10
RDY's PE(NRI) is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. RDY: 30.10 )
Ranked among companies with meaningful PE(NRI) only.
RDY' s 10-Year PE(NRI) Range
Min: 10.59  Med: 24.15 Max: 429.17
Current: 30.1
10.59
429.17
P/B 6.16
RDY's P/B is ranked lower than
69% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. RDY: 6.16 )
Ranked among companies with meaningful P/B only.
RDY' s 10-Year P/B Range
Min: 1.27  Med: 5.03 Max: 11.54
Current: 6.16
1.27
11.54
P/S 4.76
RDY's P/S is ranked lower than
60% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. RDY: 4.76 )
Ranked among companies with meaningful P/S only.
RDY' s 10-Year P/S Range
Min: 0.94  Med: 3.16 Max: 10.59
Current: 4.76
0.94
10.59
PFCF 70.98
RDY's PFCF is ranked lower than
63% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. RDY: 70.98 )
Ranked among companies with meaningful PFCF only.
RDY' s 10-Year PFCF Range
Min: 9.89  Med: 51.93 Max: 316.29
Current: 70.98
9.89
316.29
POCF 27.48
RDY's POCF is ranked higher than
55% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. RDY: 27.48 )
Ranked among companies with meaningful POCF only.
RDY' s 10-Year POCF Range
Min: 6.8  Med: 24.34 Max: 332.21
Current: 27.48
6.8
332.21
EV-to-EBIT 23.52
RDY's EV-to-EBIT is ranked higher than
54% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. RDY: 23.52 )
Ranked among companies with meaningful EV-to-EBIT only.
RDY' s 10-Year EV-to-EBIT Range
Min: -7942.7  Med: 20.40 Max: 1608.3
Current: 23.52
-7942.7
1608.3
PEG 0.82
RDY's PEG is ranked higher than
87% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. RDY: 0.82 )
Ranked among companies with meaningful PEG only.
RDY' s 10-Year PEG Range
Min: 0.26  Med: 0.69 Max: 1.97
Current: 0.82
0.26
1.97
Shiller P/E 46.45
RDY's Shiller P/E is ranked lower than
55% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. RDY: 46.45 )
Ranked among companies with meaningful Shiller P/E only.
RDY' s 10-Year Shiller P/E Range
Min: 16.23  Med: 47.21 Max: 116.49
Current: 46.45
16.23
116.49
Current Ratio 1.87
RDY's Current Ratio is ranked lower than
60% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. RDY: 1.87 )
Ranked among companies with meaningful Current Ratio only.
RDY' s 10-Year Current Ratio Range
Min: 1.07  Med: 1.73 Max: 5.03
Current: 1.87
1.07
5.03
Quick Ratio 1.47
RDY's Quick Ratio is ranked lower than
55% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. RDY: 1.47 )
Ranked among companies with meaningful Quick Ratio only.
RDY' s 10-Year Quick Ratio Range
Min: 0.7  Med: 1.19 Max: 4.1
Current: 1.47
0.7
4.1
Days Inventory 153.47
RDY's Days Inventory is ranked lower than
68% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. RDY: 153.47 )
Ranked among companies with meaningful Days Inventory only.
RDY' s 10-Year Days Inventory Range
Min: 77.02  Med: 136.83 Max: 156
Current: 153.47
77.02
156
Days Sales Outstanding 124.17
RDY's Days Sales Outstanding is ranked lower than
79% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. RDY: 124.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDY' s 10-Year Days Sales Outstanding Range
Min: 42.16  Med: 76.70 Max: 116.87
Current: 124.17
42.16
116.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.48
RDY's Dividend Yield is ranked lower than
78% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. RDY: 0.48 )
Ranked among companies with meaningful Dividend Yield only.
RDY' s 10-Year Dividend Yield Range
Min: 0.46  Med: 0.68 Max: 0.97
Current: 0.48
0.46
0.97
Dividend Payout 0.14
RDY's Dividend Payout is ranked higher than
82% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. RDY: 0.14 )
Ranked among companies with meaningful Dividend Payout only.
RDY' s 10-Year Dividend Payout Range
Min: 0.12  Med: 0.14 Max: 0.99
Current: 0.14
0.12
0.99
Dividend growth (3y) 17.00
RDY's Dividend growth (3y) is ranked higher than
74% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. RDY: 17.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
RDY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 44.2
Current: 17
0
44.2
Yield on cost (5-Year) 1.19
RDY's Yield on cost (5-Year) is ranked lower than
57% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. RDY: 1.19 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RDY' s 10-Year Yield on cost (5-Year) Range
Min: 1.14  Med: 1.69 Max: 2.4
Current: 1.19
1.14
2.4
Share Buyback Rate -0.10
RDY's Share Buyback Rate is ranked higher than
79% of the 463 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.00 vs. RDY: -0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
RDY' s 10-Year Share Buyback Rate Range
Min: -0.1  Med: -0.35 Max: -6.6
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 21.24
RDY's Price/Net Current Asset Value is ranked lower than
81% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.66 vs. RDY: 21.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RDY' s 10-Year Price/Net Current Asset Value Range
Min: 11.29  Med: 17.91 Max: 46.38
Current: 21.24
11.29
46.38
Price/Tangible Book 7.88
RDY's Price/Tangible Book is ranked lower than
69% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. RDY: 7.88 )
Ranked among companies with meaningful Price/Tangible Book only.
RDY' s 10-Year Price/Tangible Book Range
Min: 4.14  Med: 7.33 Max: 17.05
Current: 7.88
4.14
17.05
Price/Projected FCF 4.33
RDY's Price/Projected FCF is ranked lower than
53% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. RDY: 4.33 )
Ranked among companies with meaningful Price/Projected FCF only.
RDY' s 10-Year Price/Projected FCF Range
Min: 1.5  Med: 3.01 Max: 4.3
Current: 4.33
1.5
4.3
Price/DCF (Earnings Based) 3.84
RDY's Price/DCF (Earnings Based) is ranked lower than
79% of the 56 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. RDY: 3.84 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.59
RDY's Price/Median PS Value is ranked lower than
51% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. RDY: 1.59 )
Ranked among companies with meaningful Price/Median PS Value only.
RDY' s 10-Year Price/Median PS Value Range
Min: 0.38  Med: 1.12 Max: 3.12
Current: 1.59
0.38
3.12
Price/Peter Lynch Fair Value 1.23
RDY's Price/Peter Lynch Fair Value is ranked higher than
76% of the 148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. RDY: 1.23 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
RDY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.07  Med: 1.12 Max: 1.97
Current: 1.23
1.07
1.97
Price/Graham Number 3.28
RDY's Price/Graham Number is ranked lower than
56% of the 366 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. RDY: 3.28 )
Ranked among companies with meaningful Price/Graham Number only.
RDY' s 10-Year Price/Graham Number Range
Min: 2.01  Med: 3.16 Max: 12.11
Current: 3.28
2.01
12.11
Earnings Yield (Greenblatt) (%) 4.26
RDY's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. RDY: 4.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RDY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 4.60 Max: 10.3
Current: 4.26
0.1
10.3
Forward Rate of Return (Yacktman) (%) 38.78
RDY's Forward Rate of Return (Yacktman) (%) is ranked higher than
93% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. RDY: 38.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RDY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -9.4  Med: 1.60 Max: 47.3
Current: 38.78
-9.4
47.3

Analyst Estimate

Mar16 Mar17
Revenue(Mil) 5,015 5,583
EPS($) 4.58 5.41
EPS without NRI($) 4.58 5.41

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:RDY N.Mexico, 500124.India, DRREDDY.India, RDDA.Germany,
Dr Reddy Laboratories Ltd was incorporated in India as a Private Limited Company on February 24, 1984. The Company converted to a Public Limited Company on December 6, 1985. The Company together with its subsidiaries is an India-based pharmaceutical company engaged in manufacturing of pharmaceutical products. The Company operates through three segments; Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. The Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients ("APIs"), Custom Pharmaceutical Services ("CPS"), generics, biosimilars, differentiated formulations and New Chemical Entities ("NCEs"). The Global Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company's biologics business. The Pharmaceutical Services and Active Ingredients segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The Company's differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment also includes the Company's specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The Company's products includes; Zoledronic acid, Azacitidine, Moxifloxacin, Decitabine, Donepezil 23 mg, and Sumatriptan Auto Injector. The Company's competitors include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited. Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Limited, Nycomed International Management GmbH and Zentiva N.V. The Company's manufacturing and marketing of drugs, drug products and cosmetics is governed by many statutes, regulations and guide
» More Articles for RDY

Headlines

Articles On GuruFocus.com
Emerging Market Stocks To Watch Out For Feb 17 2015 
Should You Buy Actavis? Mar 18 2014 
Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 
Dr. Reddy’s Q3 FY09 Revenue at Rs. 18,401 million, EBITDA at Rs. 3,453 million, PAT at Rs. 1,924 m Jan 20 2009 

More From Other Websites
Pill For Emerging Ills: Dr. Reddy's Profit & Stock Rise Jul 30 2015
Dr. Reddy’s Q1 FY16 Financial Results Jul 30 2015
7:23 am Dr. Reddy's reported Q1 EPS of $0.58 vs $0.51 year ago; revs +7% to $591 mln. Jul 30 2015
Dr. Reddy’s Q1 FY16 Financial Results Jul 30 2015
Dr. Reddy's to Release Q1FY16 Results on July 30, 2015 // Earnings Call Slated for July 30, 6.30 PM... Jul 23 2015
Dr. Reddy's to Release Q1FY16 Results on July 30, 2015 // Earnings Call Slated for July 30, 6.30 PM... Jul 23 2015
Dr. Reddy’s announces the Launch of MEMANTINE HYDROCHLORIDE TABLETS, USP Jul 13 2015
Dr. Reddy’s Announces the Launch of MEMANTINE HYDROCHLORIDE TABLETS, USP Jul 13 2015
Dr. Reddy’s Announces the Launch of MEMANTINE HYDROCHLORIDE TABLETS, USP Jul 13 2015
Dr. Reddy’s launches HAiROOTZTM in India – its first OTC hair growth supplement Jul 06 2015
Dr. Reddy’s Unveils New Corporate Brand Identity Jul 03 2015
Dr. Reddy’s Unveils New Corporate Brand Identity Jul 01 2015
Dr. Reddy’s Unveils New Corporate Brand Identity Jul 01 2015
New Strong Sell Stocks for June 29th - Tale of the Tape Jun 29 2015
Indian drug maker recalls two medicines from US Jun 29 2015
Dr Reddy's launches hair growth supplement Jun 19 2015
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F Jun 18 2015
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F Jun 18 2015
What Lies Ahead for the Modi Government? Jun 09 2015
Dr Reddy’s Laboratories Limited and AstraZeneca Pharma India Limited entered into a distribution... Jun 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK